|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
NZ201705A
(en)
|
1981-08-31 |
1986-03-14 |
Genentech Inc |
Recombinant dna method for production of hepatitis b surface antigen in yeast
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
DD266710A3
(de)
|
1983-06-06 |
1989-04-12 |
Ve Forschungszentrum Biotechnologie |
Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
WO1990003430A1
(en)
|
1988-09-23 |
1990-04-05 |
Cetus Corporation |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
|
FR2646437B1
(fr)
|
1989-04-28 |
1991-08-30 |
Transgene Sa |
Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
CA2140933A1
(en)
|
1992-08-21 |
1994-02-22 |
Paula M. Jardieu |
Method for treating an lfa-1 mediated disorder
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5888809A
(en)
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
|
ATE230277T1
(de)
*
|
1997-06-13 |
2003-01-15 |
Genentech Inc |
Stabilisierte antikörperformulierung
|
|
EP1798286B1
(en)
|
1997-08-01 |
2011-09-07 |
Schering Corporation |
Mammalian cell membrane proteins and related reagents
|
|
US6416973B1
(en)
|
1997-08-01 |
2002-07-09 |
Schering Corporation |
Nucleic acids encoding mammalian cell membrane protein MDL-1
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
CA2499891A1
(en)
|
2002-10-03 |
2004-04-15 |
Large Scale Biology Corporation |
Multimeric protein engineering
|
|
PT1610820E
(pt)
*
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US8034771B2
(en)
|
2006-09-08 |
2011-10-11 |
Amgen Inc. |
IL-1F6 polypeptides
|
|
JP2010526066A
(ja)
|
2007-04-23 |
2010-07-29 |
シェーリング コーポレイション |
抗mdl−1抗体
|
|
ES2540854T3
(es)
|
2007-06-29 |
2015-07-14 |
Merck Sharp & Dohme Corp. |
Usos de antagonistas MDL-1
|
|
KR20110048536A
(ko)
|
2008-08-28 |
2011-05-11 |
와이어쓰 엘엘씨 |
자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
|
|
WO2011017070A1
(en)
*
|
2009-07-28 |
2011-02-10 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
EP2473528B1
(en)
*
|
2009-09-03 |
2014-12-03 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
SG184355A1
(en)
|
2010-03-01 |
2012-11-29 |
Progenics Pharm Inc |
Concentrated protein formulations and uses thereof
|
|
SI2780373T1
(sl)
|
2011-11-16 |
2019-12-31 |
Boehringer Ingelheim International Gmbh |
Protitelesa proti IL-36R
|
|
KR102063028B1
(ko)
*
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ang2 항체를 함유하는 안정화된 제형
|
|
RU2667643C2
(ru)
|
2012-08-24 |
2018-09-21 |
Новартис Аг |
Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
|
|
US20180008707A1
(en)
|
2015-02-13 |
2018-01-11 |
Sanofi |
Stable liquid formulation for monoclonal antibodies
|
|
US10526410B2
(en)
|
2015-04-15 |
2020-01-07 |
Anaptysbio, Inc. |
Antibodies directed against interleukin 36 receptor (IL-36R)
|
|
US10166993B2
(en)
|
2015-08-05 |
2019-01-01 |
Ford Global Technologies, Llc |
Customer driving mode for vehicles
|
|
EP3601350A1
(en)
|
2017-03-27 |
2020-02-05 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies combination therapy
|
|
WO2019177883A2
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
|
|
AU2019236105B2
(en)
*
|
2018-03-14 |
2025-07-31 |
Boehringer Ingelheim International Gmbh |
Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
|
|
KR20210119407A
(ko)
|
2018-12-27 |
2021-10-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
수장 족저 농포증 치료용 항-il-36r 항체
|
|
US11730812B2
(en)
|
2019-03-08 |
2023-08-22 |
Boehringer Ingelheim International Gmbh |
Anti-IL-36R antibody formulations
|